Sol-Gel Technologies Ltd.
$70
▼
-4.84%
2026-04-21 09:27:02
www.sol-gel.com
NCM: SLGL
Explore Sol-Gel Technologies Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$228.83 M
Current Price
$70
52W High / Low
$97.97 / $4.11
Stock P/E
—
Book Value
$8.19
Dividend Yield
—
ROCE
-31.74%
ROE
-23.72%
Face Value
—
EPS
$-2.19
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
28
Beta
1.27
Debt / Equity
4.34
Current Ratio
4.37
Quick Ratio
4.37
Forward P/E
-10.99
Price / Sales
12.53
Enterprise Value
$187.34 M
EV / EBITDA
-25.04
EV / Revenue
9.66
Rating
None
Target Price
$110
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Soligenix, Inc. | $1.38 | — | $14.22 M | — | -213.96% | -2.35% | $6.23 / $1 | $0.77 |
| 2. | Processa Pharmaceuticals, Inc. | $2.71 | — | $8.25 M | — | -250.81% | -3.73% | $19.63 / $1.76 | $2.17 |
| 3. | CDT Equity Inc. | $3.35 | — | $16.81 M | — | 230.89% | 491.09% | $3,030 / $2.6 | $83.78 |
| 4. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 5. | Prelude Therapeutics Incorporated | $4.51 | — | $279.73 M | — | -118.39% | -99.45% | $5.54 / $0.72 | $0.83 |
| 6. | LENZ Therapeutics, Inc. | $10.13 | — | $319.19 M | — | -32.01% | -33.63% | $50.4 / $8.25 | $9.07 |
| 7. | Sagimet Biosciences Inc. | $6.44 | — | $206.19 M | — | -51.08% | -38.2% | $11.41 / $2.02 | $3.42 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.7 M | 0.4 M | 17.26 M | 1.03 M | 0.28 M | — |
| Operating Profit | -3.41 M | -6.29 M | 11.23 M | 9.07 M | -6.1 M | — |
| Net Profit | -2.99 M | -5.94 M | 11.61 M | -8.81 M | -5.85 M | — |
| EPS in Rs | -0.92 | -1.83 | 3.58 | -2.71 | -1.8 | -0.13 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 19.39 M | 11.54 M | 1.55 M | 3.88 M |
| Operating Profit | -7.54 M | -12.01 M | -29.3 M | -16.24 M |
| Net Profit | -6.13 M | -10.58 M | -27.24 M | -14.92 M |
| EPS in Rs | -1.89 | -3.26 | -8.39 | -4.6 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 29.92 M | 35.85 M | 45.29 M | 46.63 M |
| Total Liabilities | 7.11 M | 7 M | 6.64 M | 4.42 M |
| Equity | 22.81 M | 28.85 M | 38.64 M | 42.21 M |
| Current Assets | 26.97 M | 31.3 M | 41.17 M | 43.05 M |
| Current Liabilities | 6.17 M | 5.29 M | 4.52 M | 3.33 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 0.32 M | -13.89 M | -17.73 M | -9.48 M |
| Investing CF | -8.58 M | 26.69 M | -9.74 M | 1.7 M |
| Financing CF | 0.01 M | 0 M | 21.81 M | 0.01 M |
| Free CF | 0.28 M | -13.89 M | -17.86 M | -9.65 M |
| Capex | -0.05 M | -0 M | -0.13 M | -0.17 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 642.47% | -59.98% | — | — |
| Earnings Growth % | 61.16% | -82.52% | — | — |
| Profit Margin % | -91.7% | -1752.77% | -384.32% | — |
| Operating Margin % | -104.13% | -1885.78% | -418.34% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -102.11% | -1863.77% | -403.86% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-05-05 | 1:0.1 |